Founding Clinical Sites Program
Join the Founding Clinical Sites Program.
Shape the Future of Major Depressive Disorder (MDD) Care. Join an exclusive circle of MDD clinics as a Founding Clinical Site for Haven™. This is a rare opportunity to lead our early implementation program and help define the real-world impact of Haven™.
The Advantages of Partnership
What Founding Clinical Sites receive.
Early Therapeutic Access
Secure Haven™ devices and clinical protocols ahead of general availability, with the opportunity to shape implementation alongside our clinical team.
Academic Leadership
Collaborate on peer-reviewed research and co-authorship opportunities to enhance your institution's profile in an emerging treatment category.
Preferred Commercial Terms
Benefit from preferential pricing and priority access to commercial supply.
Distinguished Recognition
Receive named acknowledgment as a founding partner across global publications, professional presentations, and marketing materials.
Eligibility
Who we are looking for.
We are recruiting inpatient psychiatric clinics treating MDD, in the US and EU, with the clinical infrastructure and regulatory readiness to participate in an implementation study.
Inpatient psychiatric focus on treating MDD
Geographic presence within the US or EU
Clinical infrastructure equipped to support a structured implementation study
Regulatory capacity to facilitate IRB or Ethics Committee approvals
Scientific commitment to contributing data to the expanding evidence base
Program timeline
Expression of interest
Submit form below
Clinical team review
Within 5 working days
Onboarding call
Protocol and logistics review
Device deployment
Devices and training provided
Implementation study
Real-world evidence generation
Express your interest
Express your interest.
Complete the form below and our clinical partnerships team will be in touch within 5 working days.
FAQ
Frequently asked questions.
Get Involved
Rapid Neuroplasticity therapy for depression.
Join the clinical program. Partner with us.
Invest in the future of depression treatment.